SARS-CoV-2 targets mitochondria, exacerbating COVID-19 pneumonia

Area of Science:

• Cell Biology
• Virology
• Pathophysiology

Background:

• Mitochondrial damage is a common feature across various coronavirus infections, including SARS-CoV-2.
• Coronaviruses disrupt mitochondrial function in multiple cell types, including airway epithelial cells and cardiomyocytes.

Purpose of the Study:

• To elucidate the mechanisms by which coronaviruses induce mitochondrial damage and its consequences.
• To explore the role of mitochondrial dysfunction in COVID-19 pathogenesis and potential therapeutic targets.

Main Methods:

• Analysis of transcriptomic changes in nuclear-encoded mitochondrial genes.
• Investigation of viral protein interactions with host mitochondrial proteins.
• Assessment of mitochondrial function markers (depolarization, MTP opening, ETC activity, ATP synthesis, fission, apoptosis).

Main Results:

• SARS-CoV-2 infection rapidly alters gene expression, downregulating electron transport chain and ATP synthesis components.
• Viral proteins alone can induce mitochondrial depolarization, MTP opening, and apoptosis.
• Coronavirus infection impairs hypoxic pulmonary vasoconstriction (HPV) by suppressing mitochondrial oxygen sensing, contributing to hypoxemia in COVID-19.

Conclusions:

• Coronavirus-induced mitochondriopathy contributes to cellular damage, apoptosis, and impaired physiological responses like HPV.
• Mitochondrial dysfunction is a key factor in COVID-19 pathogenesis and may underlie long COVID symptoms.
• Targeting apoptosis pathways and restoring HPV show therapeutic potential in preclinical models.